Skip to main content

BC Cancer – Surrey

If you are interested in more information about a particular trial, please talk with your treating physician first, and they may contact this centre for further information if necessary.

Tumour Group / Site Trial Title Opening Date
A Randomized Phase III Trial To Evaluate the Efficacy and Safety of Mk-3475 (Pembrolizumab) as Adjuvant Therapy For Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (Ypn+) After Neoadjuvant Chemotherapy
Nov 2019

A Randomized Trial of Regional Radiotherapy In Biomarker Low Risk Node Positive Breast Cancer  (CCTG MA.39)

Sept 2019
A Phase III, Multicenter, Randomized, Open-Label Trial To Evaluate Efficacy And Safety Of Ribociclib With Endocrine Therapy As An Adjuvant Treatment In Patients With Hormone Receptor-Positive, HER2-Negative, Early Breast Cancer (NATALEE)
A Phase III, Double-Blind, Placebo-Controlled, Randomized Study of Ipatasertib in Combination with Atezolizumab and Paclitaxel as a Treatment for Patients with Locally Advanced  Unresectable or Metastatic Triple-Negative Breast Cancer (IPAT)
March 2020

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy (ATHENA)

Feb 2019

A Phase II/III Randomized Study of 
Pembrolizumab in Patients with Advanced Malignant Pleural 
Mesothelioma (CCTG IND.227)
Feb 2017
LymphomaBiology of Lymphoid Cancer (Lymphoid Study)Jan 2014

A Randomized Phase III Study of Duration of Anti-PD-1 Therapy in Metastatic Melanoma (STOP-GAP) CCTG ME.13

July 2017
 You can view a video on participating in clinical trials that was created by staff at BC Cancer's Fraser Valley Centre.

SOURCE: BC Cancer – Surrey ( )
Page printed: . Unofficial document if printed. Please refer to SOURCE for latest information.

Copyright © BC Cancer. All Rights Reserved.

    Copyright © 2020 Provincial Health Services Authority